Asciminib, a novel allosteric BCR::ABL1 inhibitor, targets the myristoyl binding pocket, with promising responses being reported in third-line treatment for chronic phase CML (CML-CP) after > 2 previous cycles of TKI [8]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.